The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience.
Yuka Kato
Disclosure not yet available
Eiki Ichihara
No relevant relationships to disclose
Katsuyuki Hotta
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Nippon Kayaku; Sanofi
Akiko Hisamoto
No relevant relationships to disclose
Nagio Takigawa
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Sanofi ; Taiho Pharmaceutical
Naoyuki Nogami
Honoraria - Chugai Pharma; Lilly
Toshiyuki Kozuki
No relevant relationships to disclose
Kenichiro Kudo
No relevant relationships to disclose
Masahiro Tabata
No relevant relationships to disclose
Tetsu Shinkai
No relevant relationships to disclose
Mitsune Tanimoto
No relevant relationships to disclose
Katsuyuki Kiura
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Nippon Kayaku; Sanofi ; Taiho Pharmaceutical